Compare BLCO & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLCO | RGEN |
|---|---|---|
| Founded | 1853 | 1981 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.6B |
| IPO Year | 2022 | 1995 |
| Metric | BLCO | RGEN |
|---|---|---|
| Price | $16.32 | $117.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 12 |
| Target Price | $18.45 | ★ $167.67 |
| AVG Volume (30 Days) | 358.5K | ★ 853.5K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 286.96 |
| EPS | N/A | ★ 0.86 |
| Revenue | ★ $5,101,000,000.00 | $141,236,000.00 |
| Revenue This Year | $8.65 | $14.30 |
| Revenue Next Year | $5.59 | $14.52 |
| P/E Ratio | ★ N/A | $136.53 |
| Revenue Growth | 6.47 | ★ 35.10 |
| 52 Week Low | $10.83 | $109.50 |
| 52 Week High | $18.92 | $175.77 |
| Indicator | BLCO | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 51.18 | 45.84 |
| Support Level | $16.26 | $110.99 |
| Resistance Level | $17.11 | $130.12 |
| Average True Range (ATR) | 0.47 | 6.30 |
| MACD | -0.02 | -0.80 |
| Stochastic Oscillator | 56.18 | 26.32 |
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.